Clinical Trial Update: Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) [Phase 2]

View source ↗

Summary

Phase 2B trial assessing efficacy and safety of Ornithine Phenylacetate in hospitalized patients with hepatic encephalopathy has completed, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy

Drugs mentioned

• Ornithine phenylacetate (ornithine phenylacetate)

Snippet

Sponsor: Ocera Therapeutics, Inc. | Conditions: Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy | Phase 2 | Status: COMPLETED | Results posted: 2021-09-16